ArticleHaemophilia : the official journal of the World Federation of Hemophilia2025
Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis.
Article in Haemophilia : the official journal of the World Federation of Hemophilia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma emicizumab concentrations and bleeding rates in children and adults with severe hemophilia A.Research and practice in thrombosis and haemostasis · 2026Observational
- Estimating the Factor VIII-Equivalent Activity of Emicizumab Using Global Assays of Haemostasis.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEmicizumab is a bispecific monoclonal antibody mimicking factor (F) VIII activity and an effective therapy for prophylaxis in people with haemophilia A (PWHA). The FVIII-equivalent activity (FVIIIeq) of emicizumab remains unknown.
objectivesTo estimate FVIIIeq of emicizumab using global assays of haemostasis. PATIENTS/
methodsWe sampled plasma from (1) PWHA of all severities and therapeutic regimens and (2) persons with severe haemophilia A on emicizumab. Thrombin generation assay (TGA) and clot formation and lysis assay (CLA) were measured by commercially available (Technothrombin, Technoclone) and turbidimetric assays, respectively. FVIII was measured by a chromogenic (CSA) and emicizumab by a modified one-stage assay (OSA). Using principal components (PC) or individual parameters as dependent and independent variables in linear regression with (1) FVIII and (2) emicizumab levels, respectively, we estimated FVIIIeq (95% CI) of emicizumab.
resultsWe collected 253 samples from 110 PWHA and 41 samples from nine individuals on emicizumab prophylaxis. TGA parameters of emicizumab-treated subjects clustered distinctly, with no correlation amongst samples with only endo-/exogenous FVIII. Consequently, FVIIIeq varied substantially between parameters: Using individual TGA parameters, endogenous thrombin potential (ETP) and thrombin peak resulted in conversion factors of 0.85 (0.60-1.24) and 0.25 (0.15-0.37) IU/dL FVIIIeq per µg/mL emicizumab, respectively. CLA parameters showed broader overlap, with an FVIIIeq estimate of 0.82 (0.44-1.38).
conclusionDistinct clustering of emicizumab and FVIII samples in TGA leads to conflicting FVIIIeq estimates between parameters, highlighting systematic limitations and questioning their clinical usefulness. A, possibly conservative, FVIIIeq conversion factor estimate as determined by the thrombin peak could range from 0.15 to 0.37.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.